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Gastrointestinal stromal tumors (GISTs) are malignant and rare form of soft tissue sarcoma of the digestive tract. The incidence
of gastrointestinal stromal tumors is very low Kramer et al. 2005 Jejunal GISTs are extremely rare. Here we present a rare case
of jejunal GIST with unusually large size at presentation. The patient presented with severe abdomen pain, exophytic growth,
and dimorphic anemia. Surgical resection of the tumor was carried out, and operative ﬁndings revealed a 15 × 10cm growth,
arising from serosal surface of jejunum, at the antimesenteric surface. Diagnosis in this case was made by subjecting the resected
specimen to immunohistochemical analysis. In view of large size of the resected tumor, and high-risk histopathological features,
imatinib mesylate 400mg once daily was given as adjuvant chemotherapy. Patient is asymptomatic without any evidence of tumor
recurrence after six months of postoperative followup. Imatinib as such is recommended in metastatic, residual or recurrent
cases of GISTs or which are surgically not removable; however, recent recommendations suggests the use of imatinib mesylate
after radical surgery in high-risk cases, because it has shown a signiﬁcant decrease in the recurrence rate, and the Food and
Drug Administration (FDA) has also approved the use of imatinib as adjuvant therapy after complete resection of localized,
primary GIST.
1.Introduction
Gastrointestinal stromal tumors (GISTs) are malignant and
rare form of soft tissue sarcoma of the digestive tract.
Most common site of presentation is stomach, but it can
crop up anywhere in the digestive tract. Two-thirds of
GISTs occur in the stomach [1] while about one-fourth
develop in the small intestine, usually in the duodenum
[2]. GISTs are uncommon mesenchymal neoplasms of the
alimentary tract. The incidence of GIST is very low (i.e., 2 in
1,00,000) while jejunal GIST is extremely rare accounting for
0.1–3% of all gastrointestinal (GI) tumors [3]. Usually they
are asymptomatic but can present as abdominal pain, bleed-
ing, or mechanical obstruction. Exophytic growths of these
tumors have been noted in 18–30% of cases [4]. We present
a rare case of jejunal GIST with unusual size of presentation
and with history of severe pain abdomen, exophytic growth,
and dimorphic anemia.
2.CaseSummary
A 38-year-male patient presented with two-month-old his-
tory of pain abdomen and feeling of heaviness in right lower
abdomen. Pain was severe in intensity and relieved only after
taking medication. Patient also gave a history of lump in
the abdomen. General physical and systemic examination
was normal. Local examination of abdomen and pelvis
revealed a hard mass measuring around 15 × 10cm in size
in the right iliac region. Complete hemogram of the patient
was suggestive of dimorphic iron deﬁciency anemia with
thrombocytosis. Routine blood biochemistry parameters of
the patient were within normal limits.
Abdominopelvic ultrasonography revealed a large hypo-
echoic lesion, in the right iliac region. No mucosal lesion
was seen on upper and lower gastrointestinal endoscopy.
Computed tomography enteroclysis showed a large well-de-
ﬁned heterodense ovoid space occupying lesion measuring2 Case Reports in Oncological Medicine
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Figure 1: Computed tomography enteroclysis showing a large well-deﬁned heterodense ovoid space occupying lesion measuring 15 × 10cm
with clumped bowel loops seen in right iliac fossa.
Figure 2: Photomicrograph (IHC stain; original magniﬁcation
×400) of immunohistochemical study showing tumor cells positive
for KIT (CD117).
15 × 10cm with clumped bowel loops seen in right iliac
fossa with intraluminal protrusion and exophytic growth
pattern, without lymphadenopathy or metastatic disease
(Figures 1(a), 1(b) and 1(c)). Surgical resection of the tumor
wascarriedout,andoperative ﬁndingsrevealeda15 ×10cm
growth,arisingfromserosalsurfaceofjejunaljunction,atthe
antimesenteric surface.
Macroscopically cut surface was greyish white with the
areas of haemorrhage and cystic degeneration. The neoplas-
tic cells illustrated wide spread positivity for immunocyto-
chemicalstain,CD117(aproto-oncogenealsoknownasKIT;
Figure 2). Cells were found to be negative for CK and LCA
immunochemical stains. Histopathologically, the overlying
mucosa was unremarkable, underlying submucosa, muscu-
laris propria, and serosa shows inﬁltration by plump spindle
cells with bilateral surgical margins free from tumor inﬁltra-
tion (Figures 3 and 4). The histopathological appearance and
immunohistochemical proﬁle of the mass conﬁrmed it to be
a high-grade gastrointestinal stromal tumor (size being more
than 10cms). The patient had an uneventful postoperative
course. In view of large size of the resected tumor, and high-
risk histopathological features, imatinib mesylate 400mg
Figure 3: Photomicrograph (H&E stain; original magniﬁcation
×40) showing unremarkable overlying mucosa, submucosa, mus-
cularis propria, and serosa showing inﬁltration by tumor.
Figure 4: Photomicrograph (H&E stain; original magniﬁcation
×40) showing oval to spindle cells arranged in fascicles.
once daily was given as adjuvant chemotherapy, and patient
is asymptomatic without any evidence of tumor recurrence
after six months of postoperative followup.Case Reports in Oncological Medicine 3
3. Discussion
The incidence of GIST is very low, that is, 2 in 1,00,000 while
jejunal GISTs are extremely rare, [3] accounting for 0.1–3%
of all gastrointestinal (GI) tumors [5]. The most common
site of presentation is stomach, but it can crop up anywhere
in the digestive tract. Two-thirds of GISTs occur in the
stomach [1] while about one-fourth develop in the small
intestine, usually in duodenum [2]. As per the literature,
jejunal GISTs are the rarest type among all types of GIST [3].
The most common clinical manifestation for symptomatic
GISTs is occult gastrointestinal (GI) bleeding from mucosal
ulceration and pain abdomen [6]. Five percent of GI hem-
orrhage is obscure in nature, and GISTs have been described
as one of the cause [7].
Various unusual forms and variants of the GISTs have
been described, including jejunal GIST. Immunocytochemi-
cal studies showed KIT (CD117) and CD34 immunopositiv-
ity, attributes that are restricted in the gut to the interstitial
cellsofCajal[8].TheinterstitialcellsofCajalaremesodermal
derivatives that become associated with the autonomic
myenteric plexus during development and are thought to
regulate peristalsis [8]. Today, the majority of alimentary
tract intramural tumors are interpreted as GISTs, including
tumors formerly referred to as gastrointestinal autonomic
nerve(GAN)tumorandplexosarcoma.Activatingmutations
of the KIT gene are often found in GISTs. GISTs are not
a homogeneous group of neoplasms, however. Immuno-
cytochemically, some show diﬀerentiation toward smooth
muscle,otherstowardnerve,sometowardhistiocytes,asmall
group toward smooth muscle and nerve, and another small
group shows no diﬀerentiation. GISTs also show strong site-
dependent genetic heterogeneity [8]. The tumor is a major
or minor component of certain rare syndromes, familial,
and nonfamilial functioning paraganglioma, and GIST are
uncommon tumors that occur mostly in a sporadic and iso-
latedform,occasionallyascomponentsofmultipleneoplasia
syndromes, either separately or together. Separately, they
occur in several inherited syndromes including multiple
endocrine neoplasia [8], the GIST, lentigines, and mast cell
tumor syndrome. Together, they are variably prominent
components of three syndromes: the familial paraganglioma
and gastric GIST syndrome, neuroﬁbromatosis type 1, and
the Carney triad (syndrome with paraganglioma-jejunal
GISTcombination).Thetwoformerconditionsareinherited
as autosomal dominant traits; the later does not appear to be
inherited and aﬀects young women predominantly [8].
Themaindiﬀerentialdiagnosisofbenignorasmall-sized
malignant GIST is gastrointestinal schwannomas [9]. Gastric
schwannomas are divided into two major subgroups as
mesenchymal or neuroectodermal [9]. It is crucial to diﬀer-
entiate GIST from GI schwannomas, as GI schwannomas are
biologically benign tumors with an excellent prognosis [10]
whereas GISTs carry a relatively higher malignant potential
[11]. 20–30% of the GISTs are malignant in nature but
most (70–80%) are benign [5]. On CT imaging, GI schwan-
n o m a sh a v eh o m o g e n o u sa t t e n u a t i o na n dc a nb er e a d i l y
diﬀerentiated from a large benign or malignant GIST, which
demonstrates heterogeneous enhancement due to haemor-
rhage, necrosis, and intralesional cystic changes [9]. Gas-
trointestinal schwannomas are distinctive from conventional
schwannomas, which originate from CNS or soft tissues
[9]. Diagnosis on CT imaging becomes very diﬃcult if the
mass is small and lacks ulceration and necrosis. In such
caseshistopathologyisoftenrequiredforconﬁrmingthedia-
gnosis.
Surgery is the primary treatment of choice and for
a long time has been the only eﬀective treatment for
GIST with overall 5-year survival rates of 45–55% until
2001 when Imatinib, a small molecule inhibiting the kinase
activity of c-kit, PDGFRα,a n dBCR-ABL was recognized to
be highly eﬀective in metastasized GIST and revolutionised
the treatment of metastasized and/or unresectable GIST
[12].However,anuncertaintyremainswhetheranindividual
tumor behaves benign or whether it has the potential for
metastatic spread. To date, tumor size and the mitotic index
shape the risk sheets applied in clinical practice [12]. In fact,
local recurrence and/or metastatic spread after surgery have
been seen in 40–90% of all cases treated surgically [12].
Over 95 percent of GIST cells have mutations in one of
the two genes, called KIT (CD117) and PDGFRα [12, 13].
The drug imatinib targets both of these mutated genes and
block cellular communications that result in tumor growth.
Clinical trials have shown that imatinib can kill GIST cells
that have spread (metastasized) to other parts of the body
and cannot be removed with surgery. Tumor cells depend
on activation of aberrant growth signal pathways for both
proliferation and survival [13]. These two phenomena are
intricately tied together rather than existing as separate
events [14]. In many experimental models the withdrawal
of a growth factor pathway stimulatory signal leads to cell
d e a t hb yam e c h a n i s ms u c ha sa p o p t o s i s .T h et r e a t m e n to f
a “Kit-driven” GIST cell with imatinib eﬀectively results in
withdrawal of growth factor support. Thus, there is rationale
behindtheideathatinhibitionofKitsignalingmayinactivate
molecules that are needed for GIST cell survival [13, 14].
Imatinib mesylate was ﬁrst approved by the FDA in 2001.
Imatinib mesylate is the ﬁrst and only eﬀective drug for
the treatment of gastrointestinal stromal tumor at present.
Mutated exon 11 of the KIT receptor is essential for the
pathogenesis and response to imatinib mesylate of gastroin-
testinal stromal tumor. The eﬃcacy rate (complete response
+ partial response) of imatinib mesylate is 53.8%, and the
disease-control rate (complete response + partial response
+ stable disease) is 84% [15]. Clinical trials suggest that an
increased dose of imatinib mesylate would be beneﬁcial, and
that the interruption of imatinib treatment might result in
disease progression even after a partial response. The latest
results for imatinib in GIST come from the BRF14 trial con-
ducted by the French Sarcoma Group. In this trial, after
a median followup of 35 months, patients who had stopped
therapy had a signiﬁcantly higher risk for rapid progression
than those who continued taking the drug. The 2-year
progression-free survival was 80% in those who continued
taking imatinib, compared with 16% in those who stopped
(P<. 0001). Treatment with imatinib should not be stopped
in patients with advanced GIST, because interruption of4 Case Reports in Oncological Medicine
therapy places them at a high risk for rapid progression of
the disease [15].
As per National Cancer Institute recommendations for
theGIST,patientswithtumorsizelargerthan10centimeters,
which are labelled as histopathologically high-risk category,
beneﬁted more from imatinib than those with smaller
tumors. As per ASCO-2010, and the trial by Nilsson et al.
indicates that 1 year of adjuvant treatment with imatinib
400mg/day dramatically improves recurrence-free survival
[4].Imatinib assuchis recommended in metastatic, residual,
or recurrent cases of GISTs or which are surgically not re-
movable; however, recent recommendations suggests the use
of imatinib mesylate after radical surgery in high-risk cases,
becauseithasshown14%absolutedecreaseintherecurrence
rate (97% of the patients receiving imatinib were free of re-
currence (PFS) compared to 83% in the placebo group)
[16]. In December 2008, the Food and Drug Administration
(FDA) approved the use of imatinib as adjuvant therapy for
adult patients after complete resection of localized, primary
GIST.
4. Conclusion
Giant GISTs of the jejunum are rare tumors of the digestive
tract. In cases of jejunal GIST, surgery should be considered
as primary treatment. Better understanding of the cell of
origin and immunohistochemical markers has made timely
targeted therapy possible in GIST. Their treatment has been
revolutionizedwiththeadventoftargetedmoleculartherapy,
namely, imatinib mesylate. The therapy of advanced GIST
withimatinibmesylatehasbeenmarkedlysuccessfulwhether
by cytostatic, cytotoxic, or both mechanisms. As per latest
ASCO guidelines, recurrence-free survival is increased in
patients who take one year of imatinib 400mg/day [4].
Imatinib as such is recommended in metastatic, residual,
or recurrent cases of GISTs or which are surgically not
removable; however, recent recommendations suggests the
use of imatinib mesylate as adjuvant therapy after radical
surgery in high-risk cases, because it has shown signiﬁcant
decreasein therecurrencerate [16]. Treatmentwithimatinib
should not be stopped in patients with advanced GIST,
because interruption of therapy places them at a high risk of
rapid progression of the disease [15, 16] and patients with
tumors larger than 10cms beneﬁted more from imatinib
than those with smaller tumors.
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